What's breaking now, across thousands of outlets.
MADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it seems that the most intriguing results are coming out of ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
The liver's job of clearing harmful substances from the body is so essential that the organ may have implications for addressing unexpected diseases, including Alzheimer's and heart disease.
Cuts to federal programs and the loss of enhanced subsidies on the exchanges could deepen an existing healthcare affordability crisis, according to a new report from the Commonwealth Fund.
In a brain imaging study conducted in Poland, people with strong left-wing views barely changed their political beliefs after reading counterarguments, even as they lowered their confidence in factual…
Residents and visitors joined forces in Javea on Sunday, October 25, for the sixth edition of the town’s March Against […]
Surgery Partners shareholders other than Bain Capital would receive $23.50 a share in cash; the deal is expected to close in early 2027
The attack comes as DRC continues to battle the largest and deadliest phase of the current Bundibugyo virus disease outbreak.
